This study therefore evaluates the cost-effectiveness of CDK4/6 inhibitors combined with endocrine therapy in the first- versus second-line setting for HR+/HER2- advanced breast cancer, using data from the SONIA trial and focusing on the Chinese healthcare system. Here, ERBB2 is linked to breast carcinoma.